Ignite Creation Date:
2025-12-26 @ 11:13 PM
Ignite Modification Date:
2026-03-13 @ 4:26 AM
Study NCT ID:
NCT02548312
Status:
COMPLETED
Last Update Posted:
2019-06-12
First Post:
2015-09-08
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
The Effect of Different Financial Competing Interest Statements on Readers' Perceptions of Clinical Educational Articles
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'sschroter@bmj.com', 'phone': '02073836744', 'title': 'Dr Sara Schroter', 'organization': 'BMJ'}, 'certainAgreement': {'piSponsorEmployee': True, 'restrictiveAgreement': False}}, 'adverseEventsModule': {'eventGroups': [{'id': 'EG000', 'title': 'Dyspepsia Review- Competing Interest Statement 1', 'description': 'Honoraria \\& Travel:\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received honoraria and travel expenses from Jenka Pharmaceuticals for lecturing at a conference.', 'otherNumAtRisk': 100, 'otherNumAffected': 0, 'seriousNumAtRisk': 100, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'Gout Review- Competing Interest Statement 2', 'description': 'Advisory board \\& consultancies:\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received fees from Jenka Pharmaceuticals for consultancies and being an advisory board member.', 'otherNumAtRisk': 90, 'otherNumAffected': 0, 'seriousNumAtRisk': 90, 'seriousNumAffected': 0}, {'id': 'EG002', 'title': 'Dyspepsia Review- Competing Interest Statement 3', 'description': 'Research funding:\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received research funding from Jenka Pharmaceuticals', 'otherNumAtRisk': 96, 'otherNumAffected': 0, 'seriousNumAtRisk': 96, 'seriousNumAffected': 0}, {'id': 'EG003', 'title': 'Dyspepsia Review- Competing Interest Statement 4', 'description': 'None:\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has no competing interests.', 'otherNumAtRisk': 87, 'otherNumAffected': 0, 'seriousNumAtRisk': 87, 'seriousNumAffected': 0}, {'id': 'EG004', 'title': 'Gout Review- Competing Interest Statement 1', 'description': 'Honoraria \\& travel:\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received honoraria and travel expenses from Jenka Pharmaceuticals for lecturing at a conference.', 'otherNumAtRisk': 99, 'otherNumAffected': 0, 'seriousNumAtRisk': 99, 'seriousNumAffected': 0}, {'id': 'EG005', 'title': 'Dyspepsia Review- Competing Interest Statement 2', 'description': 'Advisory board \\& consultancies.\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received fees from Jenka Pharmaceuticals for consultancies and being an advisory board member.', 'otherNumAtRisk': 93, 'otherNumAffected': 0, 'seriousNumAtRisk': 93, 'seriousNumAffected': 0}, {'id': 'EG006', 'title': 'Gout Review- Competing Interest Statement 3', 'description': 'Research funding:\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received research funding from Jenka Pharmaceuticals..', 'otherNumAtRisk': 93, 'otherNumAffected': 0, 'seriousNumAtRisk': 93, 'seriousNumAffected': 0}, {'id': 'EG007', 'title': 'Gout Review- Competing Interest Statement 4', 'description': 'None:\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has no competing interests.', 'otherNumAtRisk': 91, 'otherNumAffected': 0, 'seriousNumAtRisk': 91, 'seriousNumAffected': 0}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': "The Readers' Level of Confidence in the Conclusions Drawn in the Article.", 'denoms': [{'units': 'Participants', 'counts': [{'value': '100', 'groupId': 'OG000'}, {'value': '89', 'groupId': 'OG001'}, {'value': '95', 'groupId': 'OG002'}, {'value': '87', 'groupId': 'OG003'}, {'value': '99', 'groupId': 'OG004'}, {'value': '92', 'groupId': 'OG005'}, {'value': '93', 'groupId': 'OG006'}, {'value': '90', 'groupId': 'OG007'}]}], 'groups': [{'id': 'OG000', 'title': 'Dyspepsia Review- Competing Interest Statement 1', 'description': 'Honoraria \\& Travel:\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received honoraria and travel expenses from Jenka Pharmaceuticals for lecturing at a conference.'}, {'id': 'OG001', 'title': 'Gout Review- Competing Interest Statement 2', 'description': 'Advisory board \\& consultancies:\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received fees from Jenka Pharmaceuticals for consultancies and being an advisory board member.'}, {'id': 'OG002', 'title': 'Dyspepsia Review- Competing Interest Statement 3', 'description': 'Research funding:\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received research funding from Jenka Pharmaceuticals'}, {'id': 'OG003', 'title': 'Dyspepsia Review- Competing Interest Statement 4', 'description': 'None:\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has no competing interests.'}, {'id': 'OG004', 'title': 'Gout Review- Competing Interest Statement 1', 'description': 'Honoraria \\& travel:\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received honoraria and travel expenses from Jenka Pharmaceuticals for lecturing at a conference.'}, {'id': 'OG005', 'title': 'Dyspepsia Review- Competing Interest Statement 2', 'description': 'Advisory board \\& consultancies.\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received fees from Jenka Pharmaceuticals for consultancies and being an advisory board member.'}, {'id': 'OG006', 'title': 'Gout Review- Competing Interest Statement 3', 'description': 'Research funding:\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received research funding from Jenka Pharmaceuticals..'}, {'id': 'OG007', 'title': 'Gout Review- Competing Interest Statement 4', 'description': 'None:\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has no competing interests.'}], 'classes': [{'categories': [{'measurements': [{'value': '6.2', 'groupId': 'OG000', 'lowerLimit': '5.8', 'upperLimit': '6.6'}, {'value': '7.0', 'groupId': 'OG001', 'lowerLimit': '6.7', 'upperLimit': '7.4'}, {'value': '6.1', 'groupId': 'OG002', 'lowerLimit': '5.7', 'upperLimit': '6.5'}, {'value': '6.4', 'groupId': 'OG003', 'lowerLimit': '6.0', 'upperLimit': '6.8'}, {'value': '7.1', 'groupId': 'OG004', 'lowerLimit': '6.8', 'upperLimit': '7.5'}, {'value': '6.2', 'groupId': 'OG005', 'lowerLimit': '5.8', 'upperLimit': '6.6'}, {'value': '7.4', 'groupId': 'OG006', 'lowerLimit': '7.1', 'upperLimit': '7.8'}, {'value': '7.4', 'groupId': 'OG007', 'lowerLimit': '7.0', 'upperLimit': '7.8'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Outcome measure will be assessed only at the time of the intervention (0 weeks). Readers will be asked to complete the study questionnaire immediately after reading the review article.', 'description': 'Measured on a single-item 10-point Likert scale from (1) "not at all confident" to (10) "extremely confident". Higher scores indicate more confidence. Min score = 0, max score =10.', 'unitOfMeasure': 'score on a scale', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': "One participant in the Group 'Gout review- competing interest statement 2', one in 'Dyspepsia review- competing interest statement 2', one in 'Dyspepsia- statement 3', and one in 'Gout- statement 4' did not respond to the question related to the primary outcome. Hence, for this outcome the numbers analyzed= 89, 92, 95 and 90, respectively."}, {'type': 'SECONDARY', 'title': 'Importance of the Article.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '100', 'groupId': 'OG000'}, {'value': '90', 'groupId': 'OG001'}, {'value': '95', 'groupId': 'OG002'}, {'value': '87', 'groupId': 'OG003'}, {'value': '99', 'groupId': 'OG004'}, {'value': '93', 'groupId': 'OG005'}, {'value': '93', 'groupId': 'OG006'}, {'value': '90', 'groupId': 'OG007'}]}], 'groups': [{'id': 'OG000', 'title': 'Dyspepsia Review- Competing Interest Statement 1', 'description': 'Honoraria \\& Travel:\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received honoraria and travel expenses from Jenka Pharmaceuticals for lecturing at a conference.'}, {'id': 'OG001', 'title': 'Gout Review- Competing Interest Statement 2', 'description': 'Advisory board \\& consultancies:\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received fees from Jenka Pharmaceuticals for consultancies and being an advisory board member.'}, {'id': 'OG002', 'title': 'Dyspepsia Review- Competing Interest Statement 3', 'description': 'Research funding:\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received research funding from Jenka Pharmaceuticals'}, {'id': 'OG003', 'title': 'Dyspepsia Review- Competing Interest Statement 4', 'description': 'None:\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has no competing interests.'}, {'id': 'OG004', 'title': 'Gout Review- Competing Interest Statement 1', 'description': 'Honoraria \\& travel:\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received honoraria and travel expenses from Jenka Pharmaceuticals for lecturing at a conference.'}, {'id': 'OG005', 'title': 'Dyspepsia Review- Competing Interest Statement 2', 'description': 'Advisory board \\& consultancies.\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received fees from Jenka Pharmaceuticals for consultancies and being an advisory board member.'}, {'id': 'OG006', 'title': 'Gout Review- Competing Interest Statement 3', 'description': 'Research funding:\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received research funding from Jenka Pharmaceuticals..'}, {'id': 'OG007', 'title': 'Gout Review- Competing Interest Statement 4', 'description': 'None:\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has no competing interests.'}], 'classes': [{'categories': [{'measurements': [{'value': '6.3', 'groupId': 'OG000', 'lowerLimit': '6.0', 'upperLimit': '6.7'}, {'value': '6.4', 'groupId': 'OG001', 'lowerLimit': '6.1', 'upperLimit': '6.8'}, {'value': '6.3', 'groupId': 'OG002', 'lowerLimit': '5.9', 'upperLimit': '6.7'}, {'value': '6.3', 'groupId': 'OG003', 'lowerLimit': '5.9', 'upperLimit': '6.7'}, {'value': '6.9', 'groupId': 'OG004', 'lowerLimit': '6.6', 'upperLimit': '7.3'}, {'value': '6.5', 'groupId': 'OG005', 'lowerLimit': '6.2', 'upperLimit': '6.9'}, {'value': '6.7', 'groupId': 'OG006', 'lowerLimit': '6.4', 'upperLimit': '7.1'}, {'value': '7.0', 'groupId': 'OG007', 'lowerLimit': '6.6', 'upperLimit': '7.4'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Outcome measure will be assessed only at the time of the intervention (0 weeks)', 'description': 'Measured on a single-item 10-point Likert scale from (1) "not at all important" to (10) "extremely important". Higher scores indicate more importance. Min score = 0, max score =10.\n\nReaders will be asked to complete the study questionnaire immediately after reading the review article.', 'unitOfMeasure': 'score on a scale', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': "One participant in the Group 'Gout review- competing interest statement 4' and one participant in 'Dyspepasia review- competing interest statement 3' did not respond to the question related to this outcome. Hence, for this outcome the numbers analyzed= 90 and 95 respectively (n=91 and n=96 in the participant flow chart)."}, {'type': 'SECONDARY', 'title': 'Interest in the Article.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '100', 'groupId': 'OG000'}, {'value': '90', 'groupId': 'OG001'}, {'value': '95', 'groupId': 'OG002'}, {'value': '87', 'groupId': 'OG003'}, {'value': '99', 'groupId': 'OG004'}, {'value': '92', 'groupId': 'OG005'}, {'value': '93', 'groupId': 'OG006'}, {'value': '90', 'groupId': 'OG007'}]}], 'groups': [{'id': 'OG000', 'title': 'Dyspepsia Review- Competing Interest Statement 1', 'description': 'Honoraria \\& Travel:\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received honoraria and travel expenses from Jenka Pharmaceuticals for lecturing at a conference.'}, {'id': 'OG001', 'title': 'Gout Review- Competing Interest Statement 2', 'description': 'Advisory board \\& consultancies:\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received fees from Jenka Pharmaceuticals for consultancies and being an advisory board member.'}, {'id': 'OG002', 'title': 'Dyspepsia Review- Competing Interest Statement 3', 'description': 'Research funding:\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received research funding from Jenka Pharmaceuticals'}, {'id': 'OG003', 'title': 'Dyspepsia Review- Competing Interest Statement 4', 'description': 'None:\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has no competing interests.'}, {'id': 'OG004', 'title': 'Gout Review- Competing Interest Statement 1', 'description': 'Honoraria \\& travel:\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received honoraria and travel expenses from Jenka Pharmaceuticals for lecturing at a conference.'}, {'id': 'OG005', 'title': 'Dyspepsia Review- Competing Interest Statement 2', 'description': 'Advisory board \\& consultancies.\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received fees from Jenka Pharmaceuticals for consultancies and being an advisory board member.'}, {'id': 'OG006', 'title': 'Gout Review- Competing Interest Statement 3', 'description': 'Research funding:\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received research funding from Jenka Pharmaceuticals..'}, {'id': 'OG007', 'title': 'Gout Review- Competing Interest Statement 4', 'description': 'None:\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has no competing interests.'}], 'classes': [{'categories': [{'measurements': [{'value': '5.9', 'groupId': 'OG000', 'lowerLimit': '5.5', 'upperLimit': '6.3'}, {'value': '6.2', 'groupId': 'OG001', 'lowerLimit': '5.9', 'upperLimit': '6.6'}, {'value': '5.8', 'groupId': 'OG002', 'lowerLimit': '5.4', 'upperLimit': '6.2'}, {'value': '5.8', 'groupId': 'OG003', 'lowerLimit': '5.4', 'upperLimit': '6.2'}, {'value': '6.7', 'groupId': 'OG004', 'lowerLimit': '6.5', 'upperLimit': '7.0'}, {'value': '6.0', 'groupId': 'OG005', 'lowerLimit': '5.6', 'upperLimit': '6.4'}, {'value': '6.5', 'groupId': 'OG006', 'lowerLimit': '6.2', 'upperLimit': '6.9'}, {'value': '7.0', 'groupId': 'OG007', 'lowerLimit': '6.7', 'upperLimit': '7.4'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Outcome measure will be assessed only at the time of the intervention (0 weeks)', 'description': 'Measured on a single-item 10-point Likert scale from (1) "not at all interesting" to (10) "extremely interesting". Higher scores indicate more interest. Min score = 0, max score =10.\n\nReaders will be asked to complete the study questionnaire immediately after reading the review article.', 'unitOfMeasure': 'score on a scale', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': "One participant in the Group 'Dyspepsia review- competing interest statement 2', 'Dyspepsia review- statement 3', 'Gout review- statement 4' did not respond to the question related to this outcome. Hence, for this outcome the numbers analyzed= 92, 90 and 95 respectively (however n=93, 91 and 96 in participant flowchart)."}, {'type': 'SECONDARY', 'title': 'Number of Participants Who Are Extremely Likely to Change Practice on the Basis of the Article (Scored a "10"), for Those Currently Treating the Relevant Condition', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '17', 'groupId': 'OG001'}, {'value': '29', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '16', 'groupId': 'OG004'}, {'value': '19', 'groupId': 'OG005'}, {'value': '11', 'groupId': 'OG006'}, {'value': '15', 'groupId': 'OG007'}]}], 'groups': [{'id': 'OG000', 'title': 'Dyspepsia Review- Competing Interest Statement 1', 'description': 'Honoraria \\& Travel:\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received honoraria and travel expenses from Jenka Pharmaceuticals for lecturing at a conference.'}, {'id': 'OG001', 'title': 'Gout Review- Competing Interest Statement 2', 'description': 'Advisory board \\& consultancies:\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received fees from Jenka Pharmaceuticals for consultancies and being an advisory board member.'}, {'id': 'OG002', 'title': 'Dyspepsia Review- Competing Interest Statement 3', 'description': 'Research funding:\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received research funding from Jenka Pharmaceuticals'}, {'id': 'OG003', 'title': 'Dyspepsia Review- Competing Interest Statement 4', 'description': 'None:\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has no competing interests.'}, {'id': 'OG004', 'title': 'Gout Review- Competing Interest Statement 1', 'description': 'Honoraria \\& travel:\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received honoraria and travel expenses from Jenka Pharmaceuticals for lecturing at a conference.'}, {'id': 'OG005', 'title': 'Dyspepsia Review- Competing Interest Statement 2', 'description': 'Advisory board \\& consultancies.\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received fees from Jenka Pharmaceuticals for consultancies and being an advisory board member.'}, {'id': 'OG006', 'title': 'Gout Review- Competing Interest Statement 3', 'description': 'Research funding:\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received research funding from Jenka Pharmaceuticals..'}, {'id': 'OG007', 'title': 'Gout Review- Competing Interest Statement 4', 'description': 'None:\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has no competing interests.'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '2', 'groupId': 'OG005'}, {'value': '2', 'groupId': 'OG006'}, {'value': '3', 'groupId': 'OG007'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Outcome measure will be assessed only at the time of the intervention (0 weeks)', 'description': 'Measured on a single-item 10-point Likert scale from (1) "not at all likely" to (10) "extremely likely". Higher scores indicate more likely to change practice. Min score = 1, max score =10.\n\nReaders asked to complete the study questionnaire immediately after reading the review article.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Analysis only includes subset that indicated they currently treat gout/dyspepsia and own practice differed from recommendations given in the review.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Dyspepsia Review- Competing Interest Statement 1', 'description': 'Honoraria \\& Travel:\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received honoraria and travel expenses from Jenka Pharmaceuticals for lecturing at a conference.'}, {'id': 'FG001', 'title': 'Gout Review- Competing Interest Statement 2', 'description': 'Advisory board \\& consultancies:\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received fees from Jenka Pharmaceuticals for consultancies and being an advisory board member.'}, {'id': 'FG002', 'title': 'Dyspepsia Review- Competing Interest Statement 3', 'description': 'Research funding:\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received research funding from Jenka Pharmaceuticals'}, {'id': 'FG003', 'title': 'Dyspepsia Review- Competing Interest Statement 4', 'description': 'None:\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has no competing interests.'}, {'id': 'FG004', 'title': 'Gout Review- Competing Interest Statement 1', 'description': 'Honoraria \\& travel:\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received honoraria and travel expenses from Jenka Pharmaceuticals for lecturing at a conference.'}, {'id': 'FG005', 'title': 'Dyspepsia Review- Competing Interest Statement 2', 'description': 'Advisory board \\& consultancies.\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received fees from Jenka Pharmaceuticals for consultancies and being an advisory board member.'}, {'id': 'FG006', 'title': 'Gout Review- Competing Interest Statement 3', 'description': 'Research funding:\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received research funding from Jenka Pharmaceuticals..'}, {'id': 'FG007', 'title': 'Gout Review- Competing Interest Statement 4', 'description': 'None:\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has no competing interests.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '133'}, {'groupId': 'FG001', 'numSubjects': '133'}, {'groupId': 'FG002', 'numSubjects': '134'}, {'groupId': 'FG003', 'numSubjects': '133'}, {'groupId': 'FG004', 'numSubjects': '133'}, {'groupId': 'FG005', 'numSubjects': '133'}, {'groupId': 'FG006', 'numSubjects': '133'}, {'groupId': 'FG007', 'numSubjects': '133'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '100'}, {'groupId': 'FG001', 'numSubjects': '90'}, {'groupId': 'FG002', 'numSubjects': '96'}, {'groupId': 'FG003', 'numSubjects': '87'}, {'groupId': 'FG004', 'numSubjects': '99'}, {'groupId': 'FG005', 'numSubjects': '93'}, {'groupId': 'FG006', 'numSubjects': '93'}, {'groupId': 'FG007', 'numSubjects': '91'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '33'}, {'groupId': 'FG001', 'numSubjects': '43'}, {'groupId': 'FG002', 'numSubjects': '38'}, {'groupId': 'FG003', 'numSubjects': '46'}, {'groupId': 'FG004', 'numSubjects': '34'}, {'groupId': 'FG005', 'numSubjects': '40'}, {'groupId': 'FG006', 'numSubjects': '40'}, {'groupId': 'FG007', 'numSubjects': '42'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '100', 'groupId': 'BG000'}, {'value': '90', 'groupId': 'BG001'}, {'value': '96', 'groupId': 'BG002'}, {'value': '87', 'groupId': 'BG003'}, {'value': '99', 'groupId': 'BG004'}, {'value': '93', 'groupId': 'BG005'}, {'value': '93', 'groupId': 'BG006'}, {'value': '91', 'groupId': 'BG007'}, {'value': '749', 'groupId': 'BG008'}]}], 'groups': [{'id': 'BG000', 'title': 'Dyspepsia Review- Competing Interest Statement 1', 'description': 'Honoraria \\& Travel:\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received honoraria and travel expenses from Jenka Pharmaceuticals for lecturing at a conference.'}, {'id': 'BG001', 'title': 'Gout Review- Competing Interest Statement 2', 'description': 'Advisory board \\& consultancies:\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received fees from Jenka Pharmaceuticals for consultancies and being an advisory board member.'}, {'id': 'BG002', 'title': 'Dyspepsia Review- Competing Interest Statement 3', 'description': 'Research funding:\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received research funding from Jenka Pharmaceuticals'}, {'id': 'BG003', 'title': 'Dyspepsia Review- Competing Interest Statement 4', 'description': 'None:\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has no competing interests.'}, {'id': 'BG004', 'title': 'Gout Review- Competing Interest Statement 1', 'description': 'Honoraria \\& travel:\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received honoraria and travel expenses from Jenka Pharmaceuticals for lecturing at a conference.'}, {'id': 'BG005', 'title': 'Dyapepsia Review- Competing Interest Statement 2', 'description': 'Advisory board \\& consultancies.\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received fees from Jenka Pharmaceuticals for consultancies and being an advisory board member.'}, {'id': 'BG006', 'title': 'Gout Review- Competing Interest Statement 3', 'description': 'Research funding:\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received research funding from Jenka Pharmaceuticals..'}, {'id': 'BG007', 'title': 'Gout Review- Competing Interest Statement 4', 'description': 'None:\n\nWe have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has no competing interests.'}, {'id': 'BG008', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '43.5', 'groupId': 'BG000', 'lowerLimit': '23', 'upperLimit': '79'}, {'value': '45.5', 'groupId': 'BG001', 'lowerLimit': '24', 'upperLimit': '72'}, {'value': '44.7', 'groupId': 'BG002', 'lowerLimit': '25', 'upperLimit': '75'}, {'value': '42.8', 'groupId': 'BG003', 'lowerLimit': '24', 'upperLimit': '67'}, {'value': '44.9', 'groupId': 'BG004', 'lowerLimit': '25', 'upperLimit': '75'}, {'value': '42.9', 'groupId': 'BG005', 'lowerLimit': '24', 'upperLimit': '76'}, {'value': '42.8', 'groupId': 'BG006', 'lowerLimit': '24', 'upperLimit': '67'}, {'value': '42.9', 'groupId': 'BG007', 'lowerLimit': '24', 'upperLimit': '76'}, {'value': '44', 'groupId': 'BG008', 'lowerLimit': '23', 'upperLimit': '79'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'FULL_RANGE'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '52', 'groupId': 'BG000'}, {'value': '46', 'groupId': 'BG001'}, {'value': '55', 'groupId': 'BG002'}, {'value': '45', 'groupId': 'BG003'}, {'value': '53', 'groupId': 'BG004'}, {'value': '51', 'groupId': 'BG005'}, {'value': '51', 'groupId': 'BG006'}, {'value': '51', 'groupId': 'BG007'}, {'value': '404', 'groupId': 'BG008'}]}, {'title': 'Male', 'measurements': [{'value': '48', 'groupId': 'BG000'}, {'value': '44', 'groupId': 'BG001'}, {'value': '41', 'groupId': 'BG002'}, {'value': '42', 'groupId': 'BG003'}, {'value': '46', 'groupId': 'BG004'}, {'value': '42', 'groupId': 'BG005'}, {'value': '42', 'groupId': 'BG006'}, {'value': '40', 'groupId': 'BG007'}, {'value': '345', 'groupId': 'BG008'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Region of Enrollment', 'classes': [{'title': 'United Kingdom', 'categories': [{'measurements': [{'value': '100', 'groupId': 'BG000'}, {'value': '90', 'groupId': 'BG001'}, {'value': '96', 'groupId': 'BG002'}, {'value': '87', 'groupId': 'BG003'}, {'value': '99', 'groupId': 'BG004'}, {'value': '93', 'groupId': 'BG005'}, {'value': '93', 'groupId': 'BG006'}, {'value': '91', 'groupId': 'BG007'}, {'value': '749', 'groupId': 'BG008'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'participants'}, {'title': 'Type of doctor', 'classes': [{'categories': [{'title': 'Consultant', 'measurements': [{'value': '31', 'groupId': 'BG000'}, {'value': '33', 'groupId': 'BG001'}, {'value': '35', 'groupId': 'BG002'}, {'value': '33', 'groupId': 'BG003'}, {'value': '37', 'groupId': 'BG004'}, {'value': '31', 'groupId': 'BG005'}, {'value': '34', 'groupId': 'BG006'}, {'value': '30', 'groupId': 'BG007'}, {'value': '264', 'groupId': 'BG008'}]}, {'title': 'General practice', 'measurements': [{'value': '36', 'groupId': 'BG000'}, {'value': '34', 'groupId': 'BG001'}, {'value': '35', 'groupId': 'BG002'}, {'value': '29', 'groupId': 'BG003'}, {'value': '33', 'groupId': 'BG004'}, {'value': '34', 'groupId': 'BG005'}, {'value': '33', 'groupId': 'BG006'}, {'value': '29', 'groupId': 'BG007'}, {'value': '263', 'groupId': 'BG008'}]}, {'title': 'Junior doctor', 'measurements': [{'value': '33', 'groupId': 'BG000'}, {'value': '23', 'groupId': 'BG001'}, {'value': '26', 'groupId': 'BG002'}, {'value': '25', 'groupId': 'BG003'}, {'value': '29', 'groupId': 'BG004'}, {'value': '28', 'groupId': 'BG005'}, {'value': '26', 'groupId': 'BG006'}, {'value': '32', 'groupId': 'BG007'}, {'value': '222', 'groupId': 'BG008'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'OTHER', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 1065}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2016-01'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2019-06', 'completionDateStruct': {'date': '2016-05', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2019-06-11', 'studyFirstSubmitDate': '2015-09-08', 'resultsFirstSubmitDate': '2018-11-02', 'studyFirstSubmitQcDate': '2015-09-10', 'lastUpdatePostDateStruct': {'date': '2019-06-12', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2019-06-11', 'studyFirstPostDateStruct': {'date': '2015-09-14', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2019-06-12', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2016-05', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': "The Readers' Level of Confidence in the Conclusions Drawn in the Article.", 'timeFrame': 'Outcome measure will be assessed only at the time of the intervention (0 weeks). Readers will be asked to complete the study questionnaire immediately after reading the review article.', 'description': 'Measured on a single-item 10-point Likert scale from (1) "not at all confident" to (10) "extremely confident". Higher scores indicate more confidence. Min score = 0, max score =10.'}], 'secondaryOutcomes': [{'measure': 'Importance of the Article.', 'timeFrame': 'Outcome measure will be assessed only at the time of the intervention (0 weeks)', 'description': 'Measured on a single-item 10-point Likert scale from (1) "not at all important" to (10) "extremely important". Higher scores indicate more importance. Min score = 0, max score =10.\n\nReaders will be asked to complete the study questionnaire immediately after reading the review article.'}, {'measure': 'Interest in the Article.', 'timeFrame': 'Outcome measure will be assessed only at the time of the intervention (0 weeks)', 'description': 'Measured on a single-item 10-point Likert scale from (1) "not at all interesting" to (10) "extremely interesting". Higher scores indicate more interest. Min score = 0, max score =10.\n\nReaders will be asked to complete the study questionnaire immediately after reading the review article.'}, {'measure': 'Number of Participants Who Are Extremely Likely to Change Practice on the Basis of the Article (Scored a "10"), for Those Currently Treating the Relevant Condition', 'timeFrame': 'Outcome measure will be assessed only at the time of the intervention (0 weeks)', 'description': 'Measured on a single-item 10-point Likert scale from (1) "not at all likely" to (10) "extremely likely". Higher scores indicate more likely to change practice. Min score = 1, max score =10.\n\nReaders asked to complete the study questionnaire immediately after reading the review article.'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ["Readers' perceptions"], 'conditions': ['Healthy']}, 'referencesModule': {'references': [{'pmid': '30782923', 'type': 'DERIVED', 'citation': "Schroter S, Pakpoor J, Morris J, Chew M, Godlee F. Effect of different financial competing interest statements on readers' perceptions of clinical educational articles: a randomised controlled trial. BMJ Open. 2019 Feb 19;9(2):e025029. doi: 10.1136/bmjopen-2018-025029."}, {'pmid': '27288389', 'type': 'DERIVED', 'citation': "Schroter S, Pakpoor J, Morris J, Chew M, Godlee F. Effect of different financial competing interest statements on readers' perceptions of clinical educational articles: study protocol for a randomised controlled trial. BMJ Open. 2016 Jun 10;6(6):e012677. doi: 10.1136/bmjopen-2016-012677."}]}, 'descriptionModule': {'briefSummary': "Financial ties with industry are common among doctors, academics and institutions. This trial aims to investigate the influence of different types of industry-linked activities on readers' perceptions of clinical reviews. Two clinical reviews have been selected on medical topics and study participants (practicing doctors) will be sent one review each. The reviews will be identical except for the inclusion of one of four different permutations of competing interest statements. Participants will be asked to rate the one review they are sent based on the study outcomes (confidence, interest, importance and likeliness to change practice). The study focus is on educational articles as these are intended to guide patient care and convey the authors' interpretation of selected data."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Practising doctors in the UK who are members of the British Medical Association (BMA) and receive The BMJ will be included.\n\nExclusion Criteria:\n\n* BMA members who have opted out of receiving a free copy of The BMJ, public health doctors, consultant oral/dental surgeons, consultants in private practice, retired doctors and student members will be excluded.'}, 'identificationModule': {'nctId': 'NCT02548312', 'briefTitle': "The Effect of Different Financial Competing Interest Statements on Readers' Perceptions of Clinical Educational Articles", 'organization': {'class': 'OTHER', 'fullName': 'The BMJ'}, 'officialTitle': "Randomised Controlled Trial to Measure the Effect of Different Financial Competing Interest Statements on Readers' Perceptions of Clinical Educational Articles", 'orgStudyIdInfo': {'id': 'COI-RCT'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Review 1- competing interest statement 1', 'description': 'Variations of financial competing interest statements. There will be a statement that the authors have no competing interests.', 'interventionNames': ['Other: Variations of financial competing interest statements']}, {'type': 'EXPERIMENTAL', 'label': 'Review 1- competing interest statement 2', 'description': 'Variations of financial competing interest statements.', 'interventionNames': ['Other: Variations of financial competing interest statements']}, {'type': 'EXPERIMENTAL', 'label': 'Review 1- competing interest statement 3', 'description': 'Variations of financial competing interest statements.', 'interventionNames': ['Other: Variations of financial competing interest statements']}, {'type': 'EXPERIMENTAL', 'label': 'Review 1- competing interest statement 4', 'description': 'Variations of financial competing interest statements.', 'interventionNames': ['Other: Variations of financial competing interest statements']}, {'type': 'EXPERIMENTAL', 'label': 'Review 2- competing interest statement 1', 'description': 'Variations of financial competing interest statements. There will be a statement that the authors have no competing interests.', 'interventionNames': ['Other: Variations of financial competing interest statements']}, {'type': 'EXPERIMENTAL', 'label': 'Review 2- competing interest statement 2', 'description': 'Variations of financial competing interest statements.', 'interventionNames': ['Other: Variations of financial competing interest statements']}, {'type': 'EXPERIMENTAL', 'label': 'Review 2- competing interest statement 3', 'description': 'Variations of financial competing interest statements.', 'interventionNames': ['Other: Variations of financial competing interest statements']}, {'type': 'EXPERIMENTAL', 'label': 'Review 2- competing interest statement 4', 'description': 'Variations of financial competing interest statements.', 'interventionNames': ['Other: Variations of financial competing interest statements']}], 'interventions': [{'name': 'Variations of financial competing interest statements', 'type': 'OTHER', 'description': 'Participants will be randomised to receive 1 of 2 review articles on different topics. For each review there will be 4 groups. Each of the 4 groups will receive an identical version of the review article with the exception of the competing interest statement which will vary depending on group assignment.', 'armGroupLabels': ['Review 1- competing interest statement 1', 'Review 1- competing interest statement 2', 'Review 1- competing interest statement 3', 'Review 1- competing interest statement 4', 'Review 2- competing interest statement 1', 'Review 2- competing interest statement 2', 'Review 2- competing interest statement 3', 'Review 2- competing interest statement 4']}]}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Sara Schroter, PhD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'The BMJ'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'The BMJ', 'class': 'OTHER'}, 'responsibleParty': {'type': 'SPONSOR'}}}}